People gather next to a sign reading AIDS 2014 in Melbourne on July 18, 2014 AFP PHOTO
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
A new hepatitis C drug has shown early promise in patients whose infection with both HIV and hepatitis C has made them traditionally difficult to treat, said a study Saturday.The study in the Journal of the American Medical Association's (JAMA) July 23/30 issue included just over 220 people who were treated for either 12 or 24 weeks.The study ended 12-weeks after treatment ended, so responses beyond that point are unknown.Treating both infections is difficult because patients have needed to use interferon for hepatitis C, which interacts poorly with antiretroviral drugs for HIV suppression.
FOLLOW THIS ARTICLE